Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 28, 2026; 32(44): 122850
Published online Nov 28, 2026. doi: 10.3748/wjg.122850
Published online Nov 28, 2026. doi: 10.3748/wjg.122850
Table 3 Medication adherence and eradication outcomes, mean ± SD/n (%)
| Outcome | Control (n = 66) | Trimebutine (n = 66) | P value |
| Mean adherence, % | 85.0 ± 33.0 | 81.6 ± 36.8 | 0.764 |
| Adherence ≥ 80% | 53 (80.3) | 52 (78.8) | > 0.999 |
| Completed 14-day regimen | 59 (89.4) | 59 (89.4) | > 0.999 |
| Lost to follow-up for UBT | 9 (13.6) | 11 (16.7) | 0.809 |
| ITT eradication n/N (%), (95%CI) | 50/66 (75.8) (64.2-84.5) | 49/66 (74.2) (62.6-83.3) | > 0.999 |
| PP eradication, n/N (%), (95%CI) | 50/57 (87.7) (76.8-93.9) | 49/55 (89.1) (78.2-94.9) | > 0.999 |
- Citation: Gong EJ, Bang CS. Add-on trimebutine-maleate does not improve tolerability or eradication in bismuth quadruple therapy for Helicobacter pylori. World J Gastroenterol 2026; 32(44): 122850
- URL: https://www.wjgnet.com/1007-9327/full/v32/i44/122850.htm
- DOI: https://dx.doi.org/10.3748/wjg.122850